Related Experiment Video
Updated: Sep 23, 2025
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Clinical and molecular characteristics of acute myeloid leukemia with MPL mutation
Yu Chen1,2,3, Jundan Xie1,2, Zhen Shen1,2
1Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Objectives:
The current study aimed to explore the incidence of MPL mutations and the clinical and molecular characteristics of AML with MPL mutation.
Methods:
In total, 1509 patients with newly diagnosed AML were retrospectively analyzed between January 2017 and December 2020. MPL mutations were detected via next-generation sequencing. During the same period, we also enrolled 30 patients with other myeloid neoplasms (MNs) with MPL mutation, which included myelodysplastic syndrome (n = 15), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) (n = 6), and MPN (n = 9). The clinical characteristics of MPL-mutated AML and other types of MNs or MPL-wide type (MPL-wt) AML were compared, and the spectrum of co-mutations and MPL mutation profiles in MPL-mutated AML were analyzed.
Results:
MPL mutations were identified in 19 (1.26%) of 1509 patients with AML. The waterfall diagram showed that the co-mutations were mainly epigenetic modifications (TET2, IDH1, and EZH2), spliceosomes (SRSF2), and transcription factors (RUNX1). The platelet count of the AML group was significantly lower than that of the MPN group (p = 0.001). MPL mutations were commonly observed in the intracellular region in AML but the transmembrane region in MPN (p = 0.013). The MPL-mutated AML group had a lower white blood cell count and a lower rate of complete remission than the MPL wild-type AML group (p = 0.037).
Conclusion:
MPL mutations are clinically relevant in patients with AML, and they may be a novel subtype characterized by lower white blood cell counts and poor complete remission rates. However, further studies must be conducted to identify its correlated mechanism.
Insights
MPL mutations occur in 1.26% of acute myeloid leukemia (AML) patients and are associated with lower white blood cell counts and reduced complete remission rates, suggesting a distinct AML subtype.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myeloproliferative neoplasms (MPNs) and other myeloid neoplasms (MNs) are often associated with mutations in the MPL gene.
- Understanding the role of MPL mutations in acute myeloid leukemia (AML) is crucial for diagnosis and treatment.
Purpose of the Study:
- To determine the incidence of MPL mutations in AML.
- To characterize the clinical and molecular features of AML with MPL mutations.
- To compare MPL-mutated AML with other MPL-mutated myeloid neoplasms.
Main Methods:
- Retrospective analysis of 1509 newly diagnosed AML patients.
- Next-generation sequencing for MPL mutation detection.
- Comparison of clinical characteristics between MPL-mutated AML, MPL-wild-type AML, and other MPL-mutated MNs.
Main Results:
- MPL mutations were found in 1.26% of AML patients.
- Common co-mutations included epigenetic modifiers (TET2, IDH1, EZH2) and spliceosome/transcription factors (SRSF2, RUNX1).
- MPL-mutated AML exhibited lower white blood cell counts and complete remission rates compared to MPL-wild-type AML.
Conclusions:
- MPL mutations represent a clinically significant finding in AML, potentially defining a novel subtype.
- This AML subtype is characterized by distinct clinical features, including lower WBC and poorer remission rates.
- Further research is needed to elucidate the underlying mechanisms of MPL mutations in AML.
